Artiva Biotherapeutics (ARTV) Competitors $3.16 -0.11 (-3.36%) Closing price 04:00 PM EasternExtended Trading$3.30 +0.14 (+4.40%) As of 05:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock ARTV vs. ANNX, NMRA, VOR, ALMS, IMMP, TKNO, SCPH, ALLO, SGMT, and SOPHShould you be buying Artiva Biotherapeutics stock or one of its competitors? The main competitors of Artiva Biotherapeutics include Annexon (ANNX), Neumora Therapeutics (NMRA), Vor Biopharma (VOR), Alumis (ALMS), Prima BioMed (IMMP), Alpha Teknova (TKNO), scPharmaceuticals (SCPH), Allogene Therapeutics (ALLO), Sagimet Biosciences (SGMT), and SOPHiA GENETICS (SOPH). These companies are all part of the "pharmaceutical products" industry. Artiva Biotherapeutics vs. Its Competitors Annexon Neumora Therapeutics Vor Biopharma Alumis Prima BioMed Alpha Teknova scPharmaceuticals Allogene Therapeutics Sagimet Biosciences SOPHiA GENETICS Artiva Biotherapeutics (NASDAQ:ARTV) and Annexon (NASDAQ:ANNX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, media sentiment, profitability, risk, earnings, analyst recommendations, dividends and valuation. Which has preferable earnings & valuation, ARTV or ANNX? Artiva Biotherapeutics has higher revenue and earnings than Annexon. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArtiva Biotherapeutics$250K308.80-$65.37MN/AN/AAnnexonN/AN/A-$138.20M-$1.29-1.64 Do analysts recommend ARTV or ANNX? Artiva Biotherapeutics presently has a consensus target price of $17.00, indicating a potential upside of 437.97%. Annexon has a consensus target price of $12.50, indicating a potential upside of 489.62%. Given Annexon's higher probable upside, analysts clearly believe Annexon is more favorable than Artiva Biotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Artiva Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Annexon 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Does the media favor ARTV or ANNX? In the previous week, Artiva Biotherapeutics and Artiva Biotherapeutics both had 3 articles in the media. Artiva Biotherapeutics' average media sentiment score of 1.41 beat Annexon's score of 1.23 indicating that Artiva Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Artiva Biotherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Annexon 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is ARTV or ANNX more profitable? Artiva Biotherapeutics' return on equity of -42.60% beat Annexon's return on equity.Company Net Margins Return on Equity Return on Assets Artiva BiotherapeuticsN/A -42.60% -37.76% Annexon N/A -70.04%-57.67% SummaryArtiva Biotherapeutics beats Annexon on 7 of the 8 factors compared between the two stocks. Get Artiva Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARTV and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ARTV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARTV vs. The Competition Export to ExcelMetricArtiva BiotherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$77.20M$3.06B$5.76B$9.84BDividend YieldN/A2.26%3.95%4.02%P/E RatioN/A21.2231.3126.60Price / Sales308.80390.30461.30121.37Price / CashN/A44.4437.7659.36Price / Book0.528.0710.026.67Net Income-$65.37M-$54.08M$3.27B$265.59M7 Day Performance14.08%2.26%3.17%3.42%1 Month Performance6.76%3.42%4.34%1.09%1 Year Performance-71.09%18.61%44.11%23.85% Artiva Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARTVArtiva Biotherapeutics3.3304 of 5 stars$3.16-3.4%$17.00+438.0%-69.4%$77.20M$250K0.0081ANNXAnnexon2.6217 of 5 stars$2.35-3.7%$12.50+431.9%-65.1%$267.70MN/A-1.8260NMRANeumora Therapeutics2.5765 of 5 stars$1.64+0.6%$7.14+335.5%-84.8%$263.97MN/A-1.04108Positive NewsVORVor Biopharma1.8567 of 5 stars$2.04-4.7%$6.07+197.4%+124.7%$258.43MN/A-1.24140News CoverageInsider TradeGap UpALMSAlumis2.265 of 5 stars$4.85+2.1%$20.17+315.8%-61.0%$258.43MN/A0.00N/AIMMPPrima BioMed1.5254 of 5 stars$1.78+2.9%$7.00+293.3%-30.5%$253.94MN/A0.002,021Positive NewsUpcoming EarningsGap UpTKNOAlpha Teknova2.4287 of 5 stars$4.41-6.0%$10.00+126.8%-3.3%$250.99M$37.74M-10.50240SCPHscPharmaceuticals4.2537 of 5 stars$4.78+3.9%$14.00+192.9%+7.2%$245.17M$49.97M-2.6430Analyst DowngradeALLOAllogene Therapeutics2.8653 of 5 stars$1.09-0.9%$8.44+674.7%-56.7%$244.07M$20K-0.98310SGMTSagimet Biosciences2.9823 of 5 stars$7.55-1.6%$25.67+240.0%+155.9%$235.28M$2M-4.138SOPHSOPHiA GENETICS2.7354 of 5 stars$3.49+0.6%$8.00+129.2%-7.8%$234.50M$65.17M-7.93520 Related Companies and Tools Related Companies ANNX Alternatives NMRA Alternatives VOR Alternatives ALMS Alternatives IMMP Alternatives TKNO Alternatives SCPH Alternatives ALLO Alternatives SGMT Alternatives SOPH Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARTV) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThis strange black card is showing up across America"THIS is the Biggest Economic Story of 2025" While most Americans are focused on tariffs and inflation, the...Stansberry Research | SponsoredHow high will gold surge?Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and decl...Weiss Ratings | SponsoredIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Artiva Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Artiva Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access